Press Releases

Woodcliff Lake, NJ, January 3, 2012 — Eisai Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding...

Tokyo, Japan, December 15, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited...

Morphotek, a subsidiary of Eisai Inc., has decided to terminate FAR122, a study of its investigational agent farletuzumab (MORAb-003), in platinum-resistant ovarian cancer. This decision was based...

Tokyo, Japan, December 2, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, ("Eisai") announced today that the company's U.S. research subsidiary H3 Biomedicine...

Woodcliff Lake, NJ, October 25, 2011 - The Breast Cancer Research Foundation (BCRF) announced today that it has awarded a research grant to Daniel F. Hayes, MD, Director of the Breast Oncology...

Lugano, Switzerland and Woodcliff Lake, NJ, USA Sept. 23, 2011 - Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program...

Tokyo, Japan, July 19, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") today announced the launch of its novel anticancer agent Halaven in Japan for the...

Woodcliff Lake, NJ, July 13, 2011 - Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking...

Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic...

Eisai Inc. announced today that the Phase III ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of the investigational compound eritoran (E5564) will...